Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Items 301–400 of 864
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
McGrath, E. E. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318229421f · Cited by 39
Genetics of breast cancer bone metastasis: a sequential multistep pattern
Fazilaty, H., & Mehdipour, P. (2014) · Clinical & Experimental Metastasis · doi:10.1007/s10585-014-9642-9 · Cited by 39
“RANKL regulates bone resorption [116], migration [117], invasion [117, 118], bone metastasis [3, 117, 119, Fig.”
BackgroundClinical nomogram to predict bone-only metastasis in patients with early breast carcinoma
Delpech, Y., Bashour, S. I., Lousquy, R., Rouzier, R., Hess, K. R., Coutant, C., Barranger, E., Esteva, F. J., Ueno, N. T., Pusztai, L., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.308 · Cited by 39
“Several hypotheses have been developed to explain this phenomenon, including the favourable chemokine milieu or microenvironment of the bone and intrinsic molecular features of cancer cells (Kang et al, 2003; Jones et al, 2006; Smid et al, 2006; Jamieson-Gladney et al, 2011).”
BackgroundOPG, RANK and RANK ligand expression in thyroid lesions
Heymann, M., Riet, A., Goff, B. L., Battaglia, S., PAINEAU, J., & Heymann, D. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.02.004 · Cited by 39
Premetastatic niche: ready for new therapeutic interventions?
Zoccoli, A., Iuliani, M., Pantano, F., Imperatori, M., Intagliata, S., Vincenzi, B., Marchetti, P., Papapietro, N., Denaro, V., Tonini, G., et al. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.656092 · Cited by 38
“Normal gland epithelial cells express RANK and RANK--RANKL pathway is involved in the development of lactating mammary glands [48].”
BackgroundAkiyama, T., Choong, P., & Dass, C. R. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9319-y · Cited by 38
“rRANK-Fc prevents arthritic bone destruction, wear debris-induced osteolysis, metastatic bone tumour from prostate cancer and myeloma-associated bone pathology [ 5 , 7]. While the other antagonist of RANK, OPG or Fc-OPG can elicit an immunological response [29, 30], RANK-Fc does not rouse the host immune response and…”
BackgroundInfluentialTerpos, E., Efstathiou, E., Christoulas, D., Ρούσσου, Μ., Katodritou, E., & Dimopoulos, M. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902845610 · Cited by 38
“In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by OPG resulted in complete protection from paralysis and a marked reduction in tumor burden in bones but not in other organs [54,58].”
BackgroundMonoclonal Antibodies Approved for Cancer Therapy
Baldo, B. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30472-4_3 · Cited by 38
Impact of breast cancer cells´ secretome on the brain metastatic niche remodeling
Carvalho, R., Paredes, J., & Ribeiro, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.011 · Cited by 38
A seven-gene CpG-island methylation panel predicts breast cancer progression
Li, Y., Melnikov, A. A., Levenson, V., Guerra, E., Simeone, P., Alberti, S., & Deng, Y. (2015) · BMC Cancer · doi:10.1186/s12885-015-1412-9 · Cited by 38
“Corresponding, RANKL triggers the migration of cancer and melanoma cells that express the RANK receptor [99].”
BackgroundImmune regulation of bone metastasis
Capietto, A.-H., & Faccio, R. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.95 · Cited by 38
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
Heymann, D. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.03.001 · Cited by 38
Regulation of Breast Cancer-induced Bone Lesions by β-Catenin Protein Signaling
Chen, Y., Shi, H. Y., Stock, S. R., Stern, P. H., & Zhang, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294595 · Cited by 38
The osteoblast in regulation of tumor cell dormancy and bone metastasis
Zarrer, J., & Taipaleenmäki, H. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100597 · Cited by 37
“Indeed, in vitro, RANKL promotes migration of RANK expressing breast and prostate cancer cells suggesting that RANKL might attract cancer cells to bone [18,19].”
BackgroundSchmiedel, B. J., Nuebling, T., Steinbacher, J., Malinovska, A., Wende, C. M., Azuma, M., Schneider, P., Große‐Hovest, L., & Salih, H. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201792 · Cited by 37
Comparison of Increased Aromatase versus ERα in the Generation of Mammary Hyperplasia and Cancer
Díaz‐Cruz, E. S., Sugimoto, Y., Gallicano, G. I., Brueggemeier, R. W., & Furth, P. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4652 · Cited by 37
“RANKL and its receptor (RANK) are expressed in primary breast cancers in humans and breast cancer cell lines (49) and RANKL is reported to be a pivotal factor regulating incidence (20), development, and growth of murine mammary cancer (19).”
Hasebe, T., Imoto, S., Yokose, T., Ishii, G., Iwasaki, M., & Wada, N. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.09.012 · Cited by 37
“We have already reported that IDCs with a fibrotic focus (FF) are associated with a significantly higher frequency of nodal metastasis, a significantly higher frequency of lymph vessel invasion, a higher histologic grade, a significantly higher frequency of presence of tumor necrosis, a significantly larger invasive t…”
BackgroundInfluentialNarducci, P., Bareggi, R., & Nicolin, V. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2009.10.003 · Cited by 37
“The correlation of high RANK expression with osteotropism in murine models was demonstrated across diverse tumor cell types, including breast cancer and melanoma (Jones et al., 2006; Nicolin and Narducci, 2008; Nicolin et al., 2008a, 2008b).”
BackgroundLiang, Q., Wang, Y., Lu, Y., Zhu, Q., Xie, W., Tang, N., Huang, L., An, T., Zhang, D., Yan, A., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03642-7 · Cited by 36
Morrissey, C. M., Kostenuik, P. J., Brown, L. G., Vessella, R. L., & Corey, E. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-148 · Cited by 36
“However, RANKL signaling has been shown to be important for metastatic spread of tumor cells [54].”
BackgroundDiagnostic and Prognostic Use of Bone Turnover Markers
Joerger, M., & Huober, J. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-21892-7_10 · Cited by 36
Fatal attraction: why breast cancer cells home to bone
Hofbauer, L. C., Rachner, T. D., & Singh, S. K. (2008) · Breast Cancer Research · doi:10.1186/bcr1848 · Cited by 36
“Blocking RANKL-RANK signalling in these mice by OPG administration reduced the skeletal tumour burden by 50% and prevented tumour-induced paralysis [8].”
BackgroundSTAC2 negatively regulates osteoclast formation by targeting the RANK signaling complex
Jeong, E., Choi, H. K., Park, J. H., & Lee, S. Y. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0048-5 · Cited by 35
Sarink, D., Schöck, H., Johnson, T., Overvad, K., Holm, M., Tjønneland, A. M., Boutron‐Ruault, M., His, M., Kvaskoff, M., Boeing, H., et al. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0125 · Cited by 35
“RANK expression has been shown to play a role in metastasis of primary breast and prostate cancer to sources of RANKL such as bone (4, 5, 32).”
BackgroundWatanabe, J., Saitsu, A., Miki, A., Kotani, K., & Sata, N. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01060-6 · Cited by 35
Mori, K., Ando, K., Heymann, D., & Rédiní, F. (2009) · PubMed · doi:10.14670/hh-24.235 · Cited by 35
“RANKL-induced cell migration in vitro was confirmed in three different human breast cancer cell lines (MDA-MB-231, MCF-7 and Hs578T), two prostate cancer cell lines (PC3 and DU145) and a mouse B16F10 melanoma subclone (Jones et al., 2006; Mori et al., 2007c; Armstrong et al., 2008).”
BackgroundMethodInfluentialEvaluation and management of body composition changes in cancer patients
Wang, J., Tan, S., Gianotti, L. V., & Wu, G. (2023) · Nutrition · doi:10.1016/j.nut.2023.112132 · Cited by 34
Rousseau, J., Escriou, V., Perrot, P., Picarda, G. G. A., Charrier, C., Scherman, D., Heymann, D., Rédiní, F., & Trichet, V. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.89 · Cited by 34
Denosumab for the treatment of bone metastases in advanced breast cancer
Casas, A., Llombart‐Cussac, A., & Martín, M. (2013) · The Breast · doi:10.1016/j.breast.2013.05.007 · Cited by 34
RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation
Jiang, J. (2011) · Oncology Reports · doi:10.3892/or.2011.1368 · Cited by 34
“Interestingly, recent studies found that functional RANK was expressed in some primary and some secondary bone tumors, including osteosarcoma (5,6), chondrosarcoma (7), breast cancer (8), prostate cancer (9,10), renal cell cancer (11) and malignant melanoma (8).”
InfluentialIranikhah, M., Wilborn, T. W., Wensel, T. M., & Ferrell, J. B. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01092.x · Cited by 34
“Preliminary evidence suggests that RANK expression status of cancer cells directs tumor migration to bone where RANKL is abundantly expressed.(29) Several studies have concluded that blocking the RANKL-RANK interaction may prevent progression of both breast and prostate cancer in bone.”
BackgroundInflammation and skeletal metastasis
Roca, H., & McCauley, L. K. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.75 · Cited by 34
Sirinian, C., Papanastasiou, A. D., Schizas, M., Σπέλλα, Μ., Stathopoulos, G. T., Repanti, M., Zarkadis, I. K., King, T. A., & Kalofonos, H. P. (2018) · Oncogene · doi:10.1038/s41388-018-0324-y · Cited by 33
Role of RANKL in cancer development and metastasis
Okamoto, K. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01182-2 · Cited by 33
“Among the RANK-expressing metastatic cell lines, it is known that the murine melanoma cell line B16F10 does not trigger osteoclast activation [10, 25, 30].”
BackgroundInfluentialWang, J., Sun, X. G., Zhang, H., Wang, Y., & Li, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3651 · Cited by 33
Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss
Zhang, X., Rossa, C., Liu, M., Li, F., D’Silva, N. J., & Kirkwood, K. L. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.08.004 · Cited by 33
Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer
Rajpar, S., & Fizazi, K. S. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31827f123e · Cited by 33
“In vitro, RANK expression on breast and melanoma cancer cell promotes migration but also influences bone-specific chemoattraction.(35) The denosumab versus placebo ‘‘147’’ phase III in nonmetastatic CRPC(36) showed an increase in bone metastasis-free survival (29.”
BackgroundZhang, L., Teng, Y., Zhang, Y., Liu, J., Xu, L., Qu, J., Hou, K., Yang, X., Liu, Y., & Qu, X. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200312 · Cited by 33
“It has recently been reported that RANK is also expressed on cancer cells, and the RANKL/ RANK pathway induces migration of prostate cancer cells, renal cancer cells, lung cancer cells and human breast cancer cells.(3) 10e13 Since RANKL is typically expressed on osteoblasts and bone stromal cells, it is possible that…”
BackgroundFaget, J., Contat, C., Zangger, N., Peters, S., & Meylan, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.121 · Cited by 33
Pantano, F., Rossi, E. M. C., Iuliani, M., Facchinetti, A., Simonetti, S., Ribelli, G., Zoccoli, A., Vincenzi, B., Tonini, G., Zamarchi, R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58339-2 · Cited by 33
Bishop, R. T., Marino, S., Carrasco, G., Li, B., Allen, R. J., Sparatore, A., Ottewell, P. D., Mollat, P., Sims, A. H., Capulli, M., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.021 · Cited by 33
Management of Lung Cancer Presenting with Solitary Bone Metastasis
Nistor, C., Ciuche, A., Cucu, A.-P., Niţipir, C., Slavu, C. O., Şerban, B., Cursaru, A., Cretu, B. S., & Cîrstoiu, C. (2022) · Medicina · doi:10.3390/medicina58101463 · Cited by 32
“Disruption to the receptor activator of the nuclear factor kappa (RANK)–receptor activator of the nuclear factor kappa B ligand (RANKL)–osteoprotegerin (OPG) axis is the basis for the development of bone metastasis [17,18].”
BackgroundRajski, M., Vogel, B., Baty, F., Rochlitz, C. F., & Buess, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029743 · Cited by 32
“, osteoprotegerin and RANKL) plays the major role and that the bisphosphonates hinder osteolytic bone degradation, thereby releasing matrix bound growth factor, which stimulates metastatic progression [12].”
BackgroundRANKL signaling in bone physiology and cancer
Dougall, W. C. (2007) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282f335be · Cited by 32
Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications
Terpos, E., & Dimopoulos, M. A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0974-x · Cited by 32
“Recent studies established that RANKL is a chemoattractant that increases migration and invasion of RANKpositive cancer cells (bone tropism) [51, 52].”
BackgroundMercatali, L., Manna, F. L., Miserocchi, G., Liverani, C., Vita, A. D., Spadazzi, C., Bongiovanni, A., Recine, F., Amadori, D., Ghetti, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081655 · Cited by 32
“It has been shown that BC cells with high tropism to the bone often overexpress RANK [35,36].”
BackgroundNF-κB signaling and crosstalk during carcinogenesis
Brücher, B. L. D. M., Lang, F. J. W., & Jamall, I. S. (2019) · 4open · doi:10.1051/fopen/2019010 · Cited by 32
Deligiorgi, M. V., Panayiotidis, M. I., Grınıatsos, J., & Trafalis, D. T. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09997-8 · Cited by 32
Feleke, M., Feng, W., Song, D., Li, H., Rothzerg, E., Wei, Q., Kõks, S., Wood, D., Liu, Y., & Xu, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221088238 · Cited by 31
Campiglio, M., Bufalino, R., Sasso, M. S., Ferri, E., Casalini, P., Adamo, V., Fabi, A., Aiello, R., Riccardi, F., Valle, E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2658-z · Cited by 31
“These mechanisms might impair both cytotoxic and cytostatic effects of trastuzumab (reviewed in [4]), triggering resistance escape mechanisms through upregulation of other receptor activities or through perturbation of the bone microenvironment [25–27].”
BackgroundSato, K., Lee, J., Sakamoto, K., Iimura, T., Kayamori, K., Yasuda, H., Shindoh, M., Ito, M., Omura, K., & Yamaguchi, A. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.038 · Cited by 31
Bone Sarcomas: From Biology to Targeted Therapies
Gaspar, N., Giannatale, A. D., Geoerger, B., Rédiní, F., Corradini, N., Entz‐Werlé, N., Tirode, F., Marec‐Bérard, P., Gentet, J., Laurence, V., et al. (2012) · Sarcoma · doi:10.1155/2012/301975 · Cited by 31
“RANKL facilitates osteoclastogenesis, bone resorption, growth factor secretion which participates in bone destruction, tumour growth, and intraosseous migration of RANK+ cells [137].”
BackgroundZhang, G., Cheng, R., Zhang, Z., Jiang, T., Ren, S., Ma, Z., Zhao, S., Zhou, C., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/srep42979 · Cited by 31
Liu, H., Cheng, L., Cao, D., & Zhang, H. (2018) · Medical Science Monitor · doi:10.12659/msm.907038 · Cited by 31
“It has been previously reported that suppression of cell migration is essential to prevent cancer metastasis in vivo [17].”
BackgroundChanda, D., Isayeva, T., Kumar, S., Siegal, G. P., Szafran, A. A., Zinn, K. R., Reddy, V., & Ponnazhagan, S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.48 · Cited by 31
Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference
Lipton, A., Berenson, J. R., Body, J.-J., Boyce, B. F., Bruland, Ø. S., Carducci, M. A., Cleeland, C. S., Clohisy, D. R., Coleman, R. E., Cook, R. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1213 · Cited by 31
RANKL Signaling and ErbB Receptors in Breast Carcinogenesis
Zoi, I., Karamouzis, M. V., Adamopoulos, C., & Papavassiliou, A. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.009 · Cited by 30
Sung, B., Cho, S., Liu, M., & Aggarwal, B. B. (2010) · International Journal of Cancer · doi:10.1002/ijc.25868 · Cited by 30
“In addition to this, these cancer cells express RANK, the receptor for RANKL, and RANKL stimulation can induce the migration of cancer cells.(39,42,43) Pearse et al.”
BackgroundGenetic polymorphism of the OPG gene associated with breast cancer
Ney, J. T., Juhasz-Böess, I., Gruenhage, F., Graeber, S. M., Bohle, R. M., Pfreundschuh, M. G., Solomayer, E. F., & Assmann, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-40 · Cited by 30
“These data support earlier results, where RANKL was shown to play a role in breast cancer cell migration into bone [21] and underscore the potential use of RANKL inhibition in the prevention of breast cancer development.”
ResultBishop, R. T., Marino, S., de Ridder, D., Allen, R. J., Lefley, D. V., Sims, A. H., Wang, N., Ottewell, P. D., & Idris, A. I. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.032 · Cited by 30
Simatou, A., Sarantis, P., Koustas, E., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207570 · Cited by 29
“a chemotactic mechanism of action in bones [30].”
BackgroundMartinez, L. M., Labovsky, V., Calcagno, M. D. L., Davies, K. M., Rivello, H. G., Bianchi, M. S., Wernicke, A., Vallone, V. B. F., & Chasseing, N. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121421 · Cited by 29
“The cellular component includes different types of cells, including myofibroblasts, fibroblasts, myoepithelial cells, blood and lymphatic endothelial cells and their precursors, pericytes, inflammatory cells and mesenchymal stem cells (MSCs) [5].”
BackgroundFarach‐Carson, M. C., Lin, S.-H., Nalty, T., & Satcher, R. L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00163 · Cited by 29
“A decrease in autocrine RANKL stimulation might trigger RANK expressing tumor cells to be attracted by RANKL expressing osteoblasts in bone, and foster cancer homing to the marrow (93).”
BackgroundRANKL inhibition: a promising novel strategy for breast cancer treatment
González‐Suárez, E. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0646-5 · Cited by 29
“RANK expression has been reported in most primary human breast tumour samples, as well as in cancer cells present in local lymph node metastasis and in bone metastasis [ 45 , 46].”
BackgroundZenger, S., He, W., Ek‐Rylander, B., Vassiliou, D., Wedin, R., Bauer, H., & Andersson, G. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9358-4 · Cited by 29
“triggers migration of RANK-expressing human epithelial cancer cells [44].”
BackgroundRachner, T. D., Schoppet, M., Niebergall, U., & Hofbauer, L. C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.118 · Cited by 29
3D Culture Modeling of Metastatic Breast Cancer Cells in Additive Manufactured Scaffolds
Nanou, A., Lorenzo‐Moldero, I., Gazouleas, K. D., Cortese, B., & Moroni, L. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c07492 · Cited by 28
“As high expression levels of the receptor activator of NF κ B (RANK) of breast cancer cells have been associated with enhanced osteotropism, 29 we addressed the possible relationship between the ECM cell a ffi nity to di ff erent ECM proteins (COL-I or FN) and RANK expression levels.”
Park, M., Yong, J.-C., Kim, B., Ko, Y., Jang, Y., Moon, Y.-O.-H., Hyun, H., & Lim, W. (2020) · Scientific Reports · doi:10.1038/s41598-021-91721-2 · Cited by 19
Osteoclastogenesis and osteoimmunology
Feng, W. H., Xia, W., Ye, Q., & Wu, W. (2014) · Frontiers in bioscience · doi:10.2741/4242 · Cited by 27
Distinctive and selective route of PI3K/PKCα-PKCδ/RhoA-Rac1 signaling in osteoclastic cell migration
Kim, J., Kim, M. Y., Lee, K., & Jeong, D. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.042 · Cited by 27
Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line
Aletaha, M., Mansoori, B., Mohammadi, A., Fazeli, M., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.030 · Cited by 27
Caveolin‑1 enhances RANKL‑induced gastric cancer cell migration
Wang, Y., Song, Y., Che, X., Zhang, L., Wang, Q., Zhang, X., Qu, J., Li, Z., Xu, L., Zhang, Y., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6550 · Cited by 27
“In addition to being secreted by osteoclast cells, previous studies have revealed that RANKL is secreted by infiltrating T cells; whereas RANK is expressed on the surface of various cancer cells, including breast, renal and lung cancer cells (2-6).”
Gomes, I., de Almeida, B. P., Dâmaso, S., Mansinho, A., Correia, I. A., Henriques, S. C., Cruz-Duarte, R., Vilhais, G., Félix, P., Alves, P., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27576 · Cited by 27
“MDA-MB-231 TNBC cells, known to express functional RANK [20, 22], and their RANK overexpressing (RANK OE) counterparts were used as comparators.”
BackgroundMethodResultThomas, E., Lee‐Pullen, T. F., Rigby, P. J., Hartmann, P. E., Xu, J., & Zeps, N. (2012) · Stem Cells · doi:10.1002/stem.1092 · Cited by 27
Molecular mechanism of bone metastasis in breast cancer
Sui, L., Wang, J., Jiang, W. G., Song, X., & Ye, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1401113 · Cited by 26
“RANK was highly expressed on the surface of breast cancer cells, while RANKL was overexpressed in bone tissues (83, 84).”
Nano-Drug Delivery Systems for Bone Metastases: Targeting the Tumor–Bone Microenvironment
Bakir, M. A., Dawalibi, A., Mufti, M. A., Behiery, A., & Mohammad, K. S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050603 · Cited by 26
“Both tumor cell colonization and osteoclast-mediated bone resorption are facilitated by the receptor activator of nuclear factor kappa B (RANK) [7].”
Zhang, L., Teng, Y., Fan, Y., Wang, Y., Li, W., Shi, J. C., Ma, Y., Li, C., Shi, X., Qu, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4382 · Cited by 26
“RANKL promotes breast cancer cell migration and induces metastasis of breast cancer cells to the bone and lungs in vitro and in xenograft experiments [6, 9, 10], suggesting that the RANK pathway plays a role in breast cancer progression.”
BackgroundResultAn extended antibody microarray for surface profiling metastatic melanoma
Alexander, K. L., Belov, L., Huang, P., Mactier, S., Scolyer, R. A., Mann, G. J., & Christopherson, R. I. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.03.017 · Cited by 26
“Jones et al. (2006)”
Beuselinck, B., Jean-Baptiste, J., Couchy, G., Job, S., de Reyniès, A., Wolter, P., Théodore, C., Gravis, G., Rousseau, B., Albiges, L. K., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.352 · Cited by 26
“Denosumab acts directly on RANK-expressing cancer cells including breast, prostate and melanoma cells (Jones et al, 2006).”
Role of sympathetic nerves in the establishment of metastatic breast cancer cells in bone
Elefteriou, F. (2016) · Journal of bone oncology · doi:10.1016/j.jbo.2016.03.003 · Cited by 26
Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?
Punzo, F., Tortora, C., Argenziano, M., Pinto, D., Pota, E., Martino, M. D., Paola, A. D., & Rossi, F. (2020) · Oncotarget · doi:10.18632/oncotarget.27669 · Cited by 26
Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis
Madel, M., & Elefteriou, F. (2021) · Cancers · doi:10.3390/cancers13122887 · Cited by 26
Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL
Marley, K., Bracha, S., & Séguin, B. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.08.001 · Cited by 26
Potential Use of Bisphosphonates in the Prevention of Metastases in Early-Stage Breast Cancer
Coleman, R. E. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.004 · Cited by 26
RANK, RANKL and OPG Expression in Breast Cancer – Influence on Osseous Metastasis
Ney, J. T., Fehm, T. N., Juhasz-Böess, I., & Solomayer, E. (2012) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0031-1298276 · Cited by 26
“In vitro data confirms that RANKL can have a contributory effect, depending on its concentration, towards the regulation of the migration of RANK-ex-pressing, healthy epithelial cells and cancer cells [47].”
BackgroundPérez‐Martínez, F. C., Alonso, V., Sarasa, J. L., Manzarbeitia, F., Vela‐Navarrete, R., Calahorra, F. J., & Esbrit, P. (2008) · PubMed · doi:10.14670/hh-23.709 · Cited by 26
Jang, H., Choi, J., Park, J.-K., Won, G., & Seol, J. (2021) · Animals · doi:10.3390/ani11061512 · Cited by 25
“Therefore, migration is strongly associated with metastasis [35]; hence, anti-tumor activity may be expected by suppressing migration.”
BackgroundМихайлович, П. В., & Манских, В. Н. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912010142 · Cited by 25
Multifunctional Properties of RANKL/RANK in Cell Differentiation, Proliferation and Metastasis
Kukita, A., & Kukita, T. (2013) · Future Oncology · doi:10.2217/fon.13.115 · Cited by 25
“have shown that RANKL stimulation of melanoma cells induces actin polymerization and ERK1/2 phosphorylation [60].”
Novel therapies in benign and malignant bone diseases
Rachner, T. D., Hadji, P., & Hofbauer, L. C. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.02.005 · Cited by 25
“Furthermore, RANKL appears to act as a direct chemoattractant for cancer cells, promoting their migration to bone (Jones et al., 2006; Armstrong et al., 2008).”
BackgroundInfluence of marginal bone loss on peri-implantitis: Systematic review of literature
Carrasco-García, A., Castellanos‐Cosano, L., Corcuera-Flores, J., Rodriguez-Perez, A., Torrés-Lagares, D., & Machuca‐Portillo, G. (2019) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.56202 · Cited by 25
“Bisphosphonates are one such drug family that has been studied due to their ability to inhibit normal bone resorption, which entails a reduction in remodeling, for a higher bone density, better mineralization and a lower risk of bone fracture (29).”
BackgroundKim, N.-S., Kim, H.-T., Kwon, M.-C., Choi, S., Kim, Y. Y., Yoon, K., Koo, B., Kong, M.-P., Shin, J., Cho, Y., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05646-11 · Cited by 25
“RANKL, a key regulator of osteoclast differentiation and/or activation (1, 16, 20, 22), is essential for the development of a lactating mammary gland during pregnancy (10) and for the expansion of adult mammary stem cells (MaSC) in normal development (2, 17) and breast cancer (11, 36).”
BackgroundSelf-citationKim, J., Lee, M. S., Baek, J. M., Park, J., Youn, B., & Oh, J. (2015) · Bone Reports · doi:10.1016/j.bonr.2015.10.003 · Cited by 25
Saad, F., Markus, R. A., & Goessl, C. D. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07364.x · Cited by 25
Golden, D. A., Saria, E. A., & Hansen, M. F. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25024 · Cited by 24
Li, Q., & Zhang, X. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.08.037 · Cited by 24
Novel agents in the management of castration resistant prostate cancer
Garcia, J., & Chaturvedi, S. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.128185 · Cited by 24
“[63] Denosumab is a humanized monoclonal antibody against RANK-L [62] that is approved in the USA and Europe for the prevention of bone loss in patients on ADT and for the prevention of SREs in patients with bone metastases.”
Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment
Jeong, H. M., Cho, S. W., & Park, S. I. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.4.485 · Cited by 24
Chernysheva, O. A., Markina, I. G., Демидов, Л. В., Александровна, К. Н., Чулкова, С. В., Palladina, A. D., Антипова, А. С., & Tupitsyn, N. N. (2019) · Cells · doi:10.3390/cells8060627 · Cited by 24
“It seems natural that bone marrow (BM) with its advanced capillary network and a cocktail of soluble protein factors, integrins, chemokines, cell adhesion molecules, and a variety of growth factors is the most attractive niche for tumor cells [11,12].”
BackgroundTakahashi, K., Nishikawa, K. K. N., Furukawa, K., Tanishima, Y., Ishikawa, Y., Kurogochi, T., Yuda, M., Tanaka, Y., Matsumoto, A., Mitsumori, N. N. M., et al. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-06199-w · Cited by 24
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.